STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial
-
Published:2024-04
Issue:
Volume:190
Page:107508
-
ISSN:0169-5002
-
Container-title:Lung Cancer
-
language:en
-
Short-container-title:Lung Cancer
Author:
Baptiste Oudart Jean,
Garinet SimonORCID,
Leger Caroline,
Barlesi Fabrice,
Mazières Julien,
Jeannin Gaelle,
Audigier-Valette Clarisse,
Morot-Sibilot Denis,
Langlais AlexandraORCID,
Amour ElodieORCID,
Mathiot Nathalie,
Birsen GaryORCID,
Blons Hélène,
Wislez MarieORCID
Reference35 articles.
1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Sung;CA. Cancer J. Clin.,2021
2. Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations;König;Cancers,2021
3. Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer;Wu;N. Engl. J. Med.,2020
4. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial;Felip;The Lancet,2021
5. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial;O’Brien;Lancet Oncol.,2022